HRP20170886T1 - Smjesa i metoda za liječenje dijabetesa - Google Patents
Smjesa i metoda za liječenje dijabetesa Download PDFInfo
- Publication number
- HRP20170886T1 HRP20170886T1 HRP20170886TT HRP20170886T HRP20170886T1 HR P20170886 T1 HRP20170886 T1 HR P20170886T1 HR P20170886T T HRP20170886T T HR P20170886TT HR P20170886 T HRP20170886 T HR P20170886T HR P20170886 T1 HRP20170886 T1 HR P20170886T1
- Authority
- HR
- Croatia
- Prior art keywords
- mixture
- matrix
- compound
- mixtures
- delivery system
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 33
- 238000000034 method Methods 0.000 title claims 9
- 206010012601 diabetes mellitus Diseases 0.000 title claims 6
- 150000001875 compounds Chemical class 0.000 claims 18
- 239000011159 matrix material Substances 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 238000012377 drug delivery Methods 0.000 claims 4
- 239000003629 gastrointestinal hormone Substances 0.000 claims 4
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 3
- 208000008589 Obesity Diseases 0.000 claims 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 3
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 241000792859 Enema Species 0.000 claims 2
- 229920002988 biodegradable polymer Polymers 0.000 claims 2
- 239000004621 biodegradable polymer Substances 0.000 claims 2
- 238000013270 controlled release Methods 0.000 claims 2
- 239000007920 enema Substances 0.000 claims 2
- 229940079360 enema for constipation Drugs 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 150000004676 glycans Chemical class 0.000 claims 2
- 230000014759 maintenance of location Effects 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 229920001282 polysaccharide Polymers 0.000 claims 2
- 239000005017 polysaccharide Substances 0.000 claims 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims 1
- 229920000856 Amylose Polymers 0.000 claims 1
- 229920001661 Chitosan Polymers 0.000 claims 1
- 229920001287 Chondroitin sulfate Polymers 0.000 claims 1
- 229920000858 Cyclodextrin Polymers 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- 229920002907 Guar gum Polymers 0.000 claims 1
- 229920001202 Inulin Polymers 0.000 claims 1
- 229920000161 Locust bean gum Polymers 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010033307 Overweight Diseases 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- 229930182556 Polyacetal Natural products 0.000 claims 1
- 108010039918 Polylysine Proteins 0.000 claims 1
- 229920001710 Polyorthoester Polymers 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000000227 bioadhesive Substances 0.000 claims 1
- 229920001400 block copolymer Polymers 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 229940059329 chondroitin sulfate Drugs 0.000 claims 1
- 229940110456 cocoa butter Drugs 0.000 claims 1
- 235000019868 cocoa butter Nutrition 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 229960002086 dextran Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 125000005456 glyceride group Chemical group 0.000 claims 1
- 239000000665 guar gum Substances 0.000 claims 1
- 235000010417 guar gum Nutrition 0.000 claims 1
- 229960002154 guar gum Drugs 0.000 claims 1
- 239000000017 hydrogel Substances 0.000 claims 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims 1
- 229940029339 inulin Drugs 0.000 claims 1
- 210000002429 large intestine Anatomy 0.000 claims 1
- 239000000711 locust bean gum Substances 0.000 claims 1
- 235000010420 locust bean gum Nutrition 0.000 claims 1
- 239000011859 microparticle Substances 0.000 claims 1
- 230000003204 osmotic effect Effects 0.000 claims 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000001814 pectin Substances 0.000 claims 1
- 229920001277 pectin Polymers 0.000 claims 1
- 235000010987 pectin Nutrition 0.000 claims 1
- 229920000747 poly(lactic acid) Polymers 0.000 claims 1
- 239000002745 poly(ortho ester) Substances 0.000 claims 1
- 229920000058 polyacrylate Polymers 0.000 claims 1
- 229920001610 polycaprolactone Polymers 0.000 claims 1
- 239000004626 polylactic acid Substances 0.000 claims 1
- 229920000656 polylysine Polymers 0.000 claims 1
- 229920002959 polymer blend Polymers 0.000 claims 1
- 229920006324 polyoxymethylene Polymers 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 239000002511 suppository base Substances 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Child & Adolescent Psychology (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Claims (11)
1. Smjesa, naznačena time, što sadrži spoj odabrano iz grupe koja sadrži glutamin, njegove farmaceutski prihvatljive soli i njihove kombinacije, smjese su pogodne za Uporabu u metodi liječenja ili prevencije stanja ili poremećaja udruženih sa smanjenjem ili izostankom oslobađanja crijevnog hormona izlučenog iz L-stanica, stanje ili poremećaj metode biraju se između dijabetesa, metaboličkog sindroma, hipertrigliceridemije, gojaznosti i sindroma policističnih jajnika, metoda uključuje davanje osobi odgovarajuće smjese da bi se induciralo oslobađanje crijevnog hormona iz L-stanica debelog crijeva, gdje je smjesa formulirana tako da se spoj ne oslobađa u želucu ili gornjim dijelovima gastrointestinalnog trakta, pri čemu:
(a) navedena smjesa je formulirana u sistemu za dostavu lijekova koji cilja debelo crijevo, ili je formulirana za rektalnu primjenu, pri čemu se sistem za dostavu spoja bira između: smjesa sa kovalentnom vezom, smjesa obloženih polimerom, smjesa uklopljenih u matrikse, smjesa koje se oslobađaju tokom vremena, redoks-senzitivnih polimernih smjesa, bioadhezivnih smjesa, smjesa obloženih mikročesticama, smjesa s osmotskom dostavom, smjesa koje sadrže polisaharide, smjesa u kojima je spoj spojen sa topivim ili biorazgradivim polimerom i retencijskih enema; ili
(b) navedena smjesa je formulirana u sistemu za dostavu lijeka koji cilja debelo crijevo, sistem za dostavu lijeka koji cilja debelo crijevo je sistem "matriks u matriksu", što je formulacija sa kontroliranim oslobađanjem načinjena od hidrofilnog prvog matriksa koji sadrži lipofilnu fazu i amfifilnu fazu, pri čemu su lipofilna faza i amfifilna faza zajedno u drugom matriksu i navedeni drugi matriks je disperziran kroz hidrofilni prvi matriks, i gdje je spoj bar dijelom inkorporiran u amfifilnu fazu.
2. Smjesa prema patentnom zahtjevu 1, naznačena time, što je smjesa formulirana u sistemu za dostavu lijeka koji cilja debelo crijevo.
3. Smjesa prema patentnom zahtjevu 2, naznačena time, što sistem za dostavu spoja predstavlja:
(i) smjese koje sadrže polisaharid odabran između kitozana, pektina, kondroitin sulfata, ciklodekstrin dekstrana, guarove gume, inulina, amiloze i rogačeve gume; ili
(ii) smjese u kojima je spoj spojen sa topivim polimerima koji se biraju između polivinilpirolidona, piranskog kopolimera, polihidroksipropilmetakrilamid-fenola, polihidroksietil-aspartamidfenola, i polietilenoksidpolilizina supstituiranog palmitoilskim reziduama; ili
(iii) smjese u kojima je spoj spojen s biorazgradivim polimerima koji se biraju između polilaktične kiseline, poliepsilon kaprolaktona, polihidroksibuterne kiseline, poliortoestara, poliacetala, polidihidropirana, policijanoakrilata i unakrsno povezanih ili amfipatičnih blok-kopolimera ili hidrogelova; ili
(iv) smjese u kojima je spoj uklopljen u sistem "matriks u matriksu".
4. Smjesa prema bilo kojem od patentnih zahtjeva 1 do 3, naznačena time, što je sistem za dostavu koji cilja debelo crijevo, sistem "matriks u matriksu", što je formulacija sa kontroliranim oslobađanjem načinjena od hidrofilnog prvog matriksa koji sadrži lipofilnu fazu i amfifilnu fazu, pri čemu su lipofilna faza i amfifilna faza zajedno u drugom matriksu i navedeni drugi matriks je disperziran kroz hidrofilni prvi matriks, i gdje je spoj bar dijelom inkorporiran u amfifilnu fazu.
5. Smjesa prema patentnom zahtjevu 1, naznačena time, što je smjesa formulirana za rektalnu primjenu.
6. Smjesa prema patentnom zahtjevu 5, naznačena time, što se sistem za dostavu spoja bira između retencijskih enema koje sadrže baze za supozitorije, kao što su kakao maslac ili drugi gliceridi, gdje se efikasno doziranje spoja osigurava u debelom crijevu, pored drugih područja na koja može utjecati rektalnim putem primjene.
7. Uporaba smjese definirane u bilo kojem od patentnih zahtjeva 1 do 6, naznačena time, što se koristi u izradi medikamenta za uporabu u metodi liječenja ili prevencije stanja ili poremećaja udruženih sa smanjenjem ili izostankom oslobađanja crijevnog hormona izlučenog iz l-stanica, stanje ili poremećaj biraju se između dijabetesa tipa i, dijabetesa tipa ii, hipertrigliceridemije, gojaznosti, metaboličkog sindroma i sindroma policističnih jajnika.
8. Smjesa definirana u bilo kojem od patentnih zahtjeva 1 do 6, naznačena time, što se koristi u metodi liječenja ili prevencije stanja ili poremećaja udruženih sa smanjenjem ili izostankom oslobađanja crijevong hormona izlučenog iz L-stanica, stanje ili poremećaj biraju se između dijabetesa tipa I, dijabetesa tipa II, hipertrigliceridemije, gojaznosti, metaboličkog sindroma i sindroma policističnih jajnika.
9. Uporaba smjese prema patentnom zahtjevu 7 ili smjesa za uporabu u metodi prema patentnom zahtjevu 8, naznačena time, što je pojedinac čovjek obolio od dijabetesa ili stanja prekomjerne tjelesne težine i pri čemu se spoj primjenjuje u količini od 0.01 do 100 mg/kg tjelesne težine pojedinca.
10. Uporaba smjese prema patentnom zahtjevu 7 ili patentnom zahtjevu 9, ili smjesa za uporabu u metodi prema patentnom zahtjevu 8 ili patentnom zahtjevu 9, naznačena time, što se spoj primjenjuje kod sisavaca.
11. Uporaba smjese prema patentnom zahtjevu 7 ili patentnom zahtjevu 9 ili patentnom zahtjevu 10, ili smjesa za uporabu u metodi prema bilo kojem od patentnih zahtjeva 8 do 10, naznačena time, što se smjesa osigurava u obliku jedinične doze i sadrži 0.5 mg do 1 g spoja.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14395109P | 2009-01-12 | 2009-01-12 | |
| US29377310P | 2010-01-11 | 2010-01-11 | |
| EP10729620.4A EP2376077B1 (en) | 2009-01-12 | 2010-01-11 | Composition and method for treatment of diabetes |
| PCT/US2010/020629 WO2010081079A2 (en) | 2009-01-12 | 2010-01-11 | Composition and method for treatment of diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170886T1 true HRP20170886T1 (hr) | 2017-09-08 |
Family
ID=42317190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170886TT HRP20170886T1 (hr) | 2009-01-12 | 2017-06-09 | Smjesa i metoda za liječenje dijabetesa |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US8470885B2 (hr) |
| EP (1) | EP2376077B1 (hr) |
| JP (1) | JP5702306B2 (hr) |
| KR (4) | KR20110120866A (hr) |
| CN (1) | CN102355896A (hr) |
| AU (1) | AU2010203413B2 (hr) |
| BR (1) | BRPI1006145B8 (hr) |
| CA (1) | CA2748827C (hr) |
| CL (1) | CL2011001692A1 (hr) |
| CY (1) | CY1119010T1 (hr) |
| DK (1) | DK2376077T3 (hr) |
| EA (1) | EA022631B1 (hr) |
| ES (1) | ES2628233T3 (hr) |
| HR (1) | HRP20170886T1 (hr) |
| HU (1) | HUE034551T2 (hr) |
| LT (1) | LT2376077T (hr) |
| MX (1) | MX2011007393A (hr) |
| PL (1) | PL2376077T3 (hr) |
| PT (1) | PT2376077T (hr) |
| RS (1) | RS56054B1 (hr) |
| SI (1) | SI2376077T1 (hr) |
| WO (1) | WO2010081079A2 (hr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010062863A2 (en) | 2008-11-26 | 2010-06-03 | Satiogen Pharmaceuticals, Inc. | Compositions containing satiogens and methods of use |
| US20150224081A1 (en) * | 2009-01-12 | 2015-08-13 | Biokier, Inc. | Composition and method for treatment of diabetes |
| US20160184266A9 (en) * | 2009-01-12 | 2016-06-30 | Biokier, Inc | Composition and method for treatment of diabetes |
| WO2012161670A2 (en) | 2010-04-07 | 2012-11-29 | Incube Labs, Llc | Method for treating diabetes and other glucose regulation disorders using stem cells |
| EP2569430B1 (en) | 2010-05-12 | 2018-10-17 | The Trustees of Columbia University in the City of New York | Methods for producing enteroendocrine cells that make and secrete insulin |
| KR20130055220A (ko) | 2011-11-18 | 2013-05-28 | 삼성전자주식회사 | 동박적층판 및 이를 사용한 금속코어기판의 제조방법 |
| CN103945858A (zh) * | 2011-11-21 | 2014-07-23 | 埃默斯医疗股份有限公司 | 用于治疗糖尿病和相关病症的方法和组合物 |
| US20150073057A1 (en) * | 2013-09-06 | 2015-03-12 | Biokier, Inc. | Composition and method for treatment of diabetes |
| US10487314B2 (en) | 2014-06-26 | 2019-11-26 | The Trustees Of Columbia University In The City Of New York | Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells |
| WO2016172479A1 (en) * | 2015-04-22 | 2016-10-27 | Cedars-Sinai Medical Center | Enterically delivered bitter oligopeptides for the treatment for type 2 diabetes |
| WO2016210384A2 (en) | 2015-06-25 | 2016-12-29 | Synlogic, Inc. | Bacteria engineered to treat metabolic diseases |
| US9668991B1 (en) | 2015-12-09 | 2017-06-06 | International Business Machines Corporation | SCFA colonic composition |
| CN107684550B (zh) * | 2016-08-03 | 2020-04-10 | 徐天宏 | 糖尿病治疗产品及其制备与应用 |
| JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
| WO2019165309A1 (en) | 2018-02-23 | 2019-08-29 | Ambra Bioscience Llc | Compositions and methods for hunger control and weight management |
| EP3810123A1 (en) | 2018-06-20 | 2021-04-28 | Axcella Health Inc. | Compositions and methods for the treatment of fat infiltration in muscle |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA885473B (en) * | 1987-08-07 | 1989-03-29 | Century Lab Inc | Free fatty acids for treatment of diabetes mellitus |
| IT1245890B (it) * | 1991-04-12 | 1994-10-25 | Alfa Wassermann Spa | Formulazioni farmaceutiche per uso orale gastroresistenti contenenti acidi biliari. |
| AU8699298A (en) | 1997-08-11 | 1999-03-01 | Alza Corporation | Prolonged release active agent dosage form adapted for gastric retention |
| US6652882B1 (en) | 1997-10-06 | 2003-11-25 | Intellipharmaceutics Corp | Controlled release formulation containing bupropion |
| GB9722426D0 (en) | 1997-10-23 | 1997-12-24 | Univ London Pharmacy | Controlled release formulations |
| IL142650A (en) | 1998-04-08 | 2007-06-03 | Galmed Int Ltd | Use of bile acid conjugates or bile salts and fatty acids or fatty acids in the preparation of pharmaceuticals for lowering cholesterol, for the treatment of fatty liver and for the treatment of hyperglycemia and diabetes |
| ATE251449T1 (de) | 1999-06-14 | 2003-10-15 | Cosmo Spa | Geschmacksmaskierte orale pharmazeutische zusammensetzungen mit kontrollierter abgabe |
| CA2438593C (en) | 2001-02-26 | 2010-09-21 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxypyrazole derivatives and medicinal use thereof |
| US20030203004A1 (en) * | 2002-04-24 | 2003-10-30 | Kelm Gary Robert | Compositions comprising short and long chain fatty acids and methods of their use for the management of body weight |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| ES2240931T3 (es) | 2003-10-28 | 2005-10-16 | Adorkem Technology Spa | Procedimiento para la preparacion de citalopram. |
| ITMI20040187A1 (it) | 2004-02-06 | 2004-05-06 | Cosmo Spa | Composizioni farmaceutiche o dietetiche a base di acidi grassi a catena corta e zuccheri complessi per le disfunzioni intestinali |
| ITMI20041295A1 (it) | 2004-06-25 | 2004-09-25 | Cosmo Spa | Composizioni farmaceutiche antimicrobiche orali |
| JP2006056881A (ja) | 2004-07-21 | 2006-03-02 | Takeda Chem Ind Ltd | 縮合環化合物 |
| JP2006063064A (ja) | 2004-07-27 | 2006-03-09 | Takeda Chem Ind Ltd | 受容体作動剤 |
| KR20080012304A (ko) | 2005-05-23 | 2008-02-11 | 니뽄 다바코 산교 가부시키가이샤 | 피라졸 화합물 및 이들 피라졸 화합물을 포함하여이루어지는 당뇨병 치료약 |
| DE102005046237A1 (de) | 2005-09-28 | 2007-04-05 | Südzucker Aktiengesellschaft Mannheim/Ochsenfurt | Buttersäureester von Kohlenhydraten und Kohlenhydratpolyolen |
| ITMI20052000A1 (it) * | 2005-10-21 | 2007-04-22 | Promefarm S R L | Compressa gastroresitente a base di butirrato di sodio |
| AU2007243131A1 (en) | 2006-01-20 | 2007-11-08 | Smithkline Beecham Corporation | Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system |
| US20090035306A1 (en) | 2006-11-29 | 2009-02-05 | Kalypsys, Inc. | Quinazolinone modulators of tgr5 |
| AU2007331447B2 (en) * | 2006-12-15 | 2012-09-06 | Tima Foundation | Novel compositions and uses thereof |
| EP2367554A4 (en) | 2008-11-26 | 2020-03-25 | Satiogen Pharmaceuticals, Inc. | BILIARY ACID RECYCLING INHIBITORS FOR THE TREATMENT OF OBESITY AND DIABETES |
| WO2010062863A2 (en) | 2008-11-26 | 2010-06-03 | Satiogen Pharmaceuticals, Inc. | Compositions containing satiogens and methods of use |
| MX2011008448A (es) | 2009-02-10 | 2012-02-28 | Amarin Pharma Inc | Uso de ester etilico del acido eisosapentaenoico para tratar hipertrigliceridemia. |
| KR102012111B1 (ko) | 2009-06-15 | 2019-08-19 | 아마린 파마, 인크. | 병용 스타틴 요법을 받는 대상체에서 ｌｄｌ－ｃ 수준을 상승시키지 않으면서 트리글리세리드를 저하시키기 위한 조성물 및 방법 |
| SG10201405994UA (en) | 2009-09-23 | 2014-10-30 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical Composition Comprising Omega-3 Fatty Acid And Hydroxy-derivative Of A Statin And Methods Of Using Same |
-
2010
- 2010-01-11 PT PT107296204T patent/PT2376077T/pt unknown
- 2010-01-11 DK DK10729620.4T patent/DK2376077T3/en active
- 2010-01-11 BR BRPI1006145A patent/BRPI1006145B8/pt active IP Right Grant
- 2010-01-11 MX MX2011007393A patent/MX2011007393A/es active IP Right Grant
- 2010-01-11 SI SI201031473T patent/SI2376077T1/sl unknown
- 2010-01-11 KR KR1020117015982A patent/KR20110120866A/ko active Application Filing
- 2010-01-11 KR KR1020177034790A patent/KR20170138573A/ko active Search and Examination
- 2010-01-11 EP EP10729620.4A patent/EP2376077B1/en active Active
- 2010-01-11 KR KR1020197015093A patent/KR20190062609A/ko not_active Application Discontinuation
- 2010-01-11 HU HUE10729620A patent/HUE034551T2/en unknown
- 2010-01-11 CA CA2748827A patent/CA2748827C/en active Active
- 2010-01-11 ES ES10729620.4T patent/ES2628233T3/es active Active
- 2010-01-11 CN CN201080004432XA patent/CN102355896A/zh active Pending
- 2010-01-11 US US13/143,766 patent/US8470885B2/en active Active
- 2010-01-11 PL PL10729620T patent/PL2376077T3/pl unknown
- 2010-01-11 RS RS20170584A patent/RS56054B1/sr unknown
- 2010-01-11 EA EA201190068A patent/EA022631B1/ru unknown
- 2010-01-11 WO PCT/US2010/020629 patent/WO2010081079A2/en active Application Filing
- 2010-01-11 LT LTEP10729620.4T patent/LT2376077T/lt unknown
- 2010-01-11 KR KR1020177007518A patent/KR20170034928A/ko active Application Filing
- 2010-01-11 AU AU2010203413A patent/AU2010203413B2/en active Active
- 2010-01-11 JP JP2011545487A patent/JP5702306B2/ja active Active
-
2011
- 2011-07-11 CL CL2011001692A patent/CL2011001692A1/es unknown
-
2012
- 2012-10-08 US US13/646,778 patent/US8680085B2/en active Active
-
2017
- 2017-06-09 HR HRP20170886TT patent/HRP20170886T1/hr unknown
- 2017-06-12 CY CY20171100614T patent/CY1119010T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170886T1 (hr) | Smjesa i metoda za liječenje dijabetesa | |
| Kumar et al. | Metformin-loaded alginate nanoparticles as an effective antidiabetic agent for controlled drug release | |
| S Duttagupta et al. | Chitosan: a propitious biopolymer for drug delivery | |
| JP2010511433A5 (hr) | ||
| RU2018100114A (ru) | Кортикостероиды для лечения суставной боли | |
| CN102088962B (zh) | 用于皮质类固醇口服给药的组合物 | |
| JP2007535564A5 (hr) | ||
| HRP20171506T1 (hr) | Tableta otporna na mijenjanje koja pruža neposredno oslobađanje lijeka | |
| JP2017141477A5 (hr) | ||
| JP2007532640A5 (hr) | ||
| JP2010510286A5 (hr) | ||
| JP2012515163A5 (hr) | ||
| Nangare et al. | Pharmaceutical applications of electrospinning | |
| JP2005508893A5 (hr) | ||
| JP2007535566A5 (hr) | ||
| EP2120880A2 (de) | Pellets mit magensaftresistenter wirkstoff-matrix | |
| Torres-Martínez et al. | Drugs loaded into electrospun polymeric nanofibers for delivery | |
| Shams et al. | Core/shell microencapsulation of indomethacin/paracetamol by co-axial electrohydrodynamic atomization | |
| EP2054029A1 (en) | Subcutaneous implants releasing an active principle over an extended period of time | |
| Bhusnure et al. | Novel 5-flurouracil-Embedded non-woven PVA-PVP electrospun nanofibers with enhanced anti-cancer efficacy: Formulation, evaluation and in vitro anti-cancer activity | |
| JP2014511841A5 (hr) | ||
| Painuly et al. | Effect on in-vitro release of individual and dual contraceptive drug loading from gelatin electrospun fibers | |
| JP2008534563A5 (hr) | ||
| Iswandana et al. | Preparation of calcium alginate-tetrandrine beads using ionic gelation method as colon-targeted dosage form | |
| Samak et al. | A comparison of aerosolization and homogenization techniques for production of alginate microparticles for delivery of corticosteroids to the colon |